Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,380,100
  • Shares Outstanding, K 44,961
  • Annual Sales, $ 236,980 K
  • Annual Income, $ 15,420 K
  • 60-Month Beta 1.69
  • Price/Sales 18.90
  • Price/Cash Flow 604.01
  • Price/Book 6.22
Trade GKOS with:

Options Overview

Details
  • Implied Volatility 51.09%
  • Historical Volatility 37.38%
  • IV Percentile 2%
  • IV Rank 2.47%
  • IV High 178.34% on 03/16/20
  • IV Low 42.65% on 01/07/21
  • Put/Call Vol Ratio 35.50
  • Today's Volume 73
  • Volume Avg (30-Day) 110
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 5
  • Open Int (30-Day) 762

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.26
  • Low Estimate -0.46
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +20.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.80 +9.43%
on 02/18/21
99.00 -2.95%
on 03/02/21
+3.97 (+4.31%)
since 02/02/21
3-Month
66.38 +44.74%
on 12/10/20
99.00 -2.95%
on 03/02/21
+26.54 (+38.17%)
since 12/02/20
52-Week
23.31 +312.18%
on 03/23/20
99.00 -2.95%
on 03/02/21
+51.81 (+117.03%)
since 03/02/20

Most Recent Stories

More News
Glaukos Announces Participation in Oppenheimer Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 96.08 (-1.38%)
Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 96.08 (-1.38%)
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

ANGO : 21.08 (-0.85%)
HOLX : 74.82 (+0.24%)
ABT : 122.53 (+0.26%)
GKOS : 96.08 (-1.38%)
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 93.75% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

GKOS : 96.08 (-1.38%)
Glaukos: 4Q Earnings Snapshot

SAN CLEMENTE, Calif. (AP) _ Glaukos Corp. (GKOS) on Thursday reported a fourth-quarter loss of $10.6 million, after reporting a profit in the same period a year earlier.

GKOS : 96.08 (-1.38%)
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 96.08 (-1.38%)
Glaukos Announces Positive Phase 3 Trial Results for iLink(TM) Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint

--Epi-on Treatment Demonstrated the Ability to Halt or Reduce the Progression of Keratoconus versus Observed Disease Progression in a Placebo-Control Arm

GKOS : 96.08 (-1.38%)
Glaukos Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Glaukos Corp. (NYSE:GKOS) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 4:30 PM...

GKOS : 96.08 (-1.38%)
Covid 19 impact on Ophthalmic Devices Market & future outlook 2027 interpreted by a new report

The global ophthalmic devices market was valued at $32,534.0 million in 2019, and is projected to reach $44,865.0 million by 2027, registering a CAGR of 4.0 % from 2020 to 2027.

ABT : 122.53 (+0.26%)
CZMWF : 150.0000 (-2.79%)
GKOS : 96.08 (-1.38%)
NVS : 88.17 (+0.82%)
TOPCF : 12.6200 (-5.04%)
VRX.TO : 30.80 (-3.33%)
Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to...

GKOS : 96.08 (-1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe,...

See More

Key Turning Points

3rd Resistance Point 101.62
2nd Resistance Point 100.31
1st Resistance Point 98.19
Last Price 96.08
1st Support Level 94.77
2nd Support Level 93.46
3rd Support Level 91.34

See More

52-Week High 99.00
Last Price 96.08
Fibonacci 61.8% 70.09
Fibonacci 50% 61.15
Fibonacci 38.2% 52.22
52-Week Low 23.31

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar